Background: Spinal cord demyelination is common in multiple sclerosis (MS) and has been
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Spinal cord demyelination and atrophy are common in multiple sclerosis and have been linked to increased MS-related disability [1] [2] [3] [4] [5] [6] . Advances in magnetic resonance imaging (MRI) scan acquisition and segmentation techniques have led to improved ability to measure cervical spinal cord atrophy and its relationship to clinical outcomes in MS [6] [7] [8] [9] [10] [11] [12] [13] [14] . Spinal cord atrophy is associated with a progressive disease course and has been hypothesized to be an early indicator of imminent disease progression [12] [13] [14] . Although spinal cord atrophy is related to MS disability, the link between spinal cord atrophy, lesions and health-related quality-of-life (QOL) has not yet been examined. Prior work has demonstrated association between MS-related MRI brain pathology (lesion volume and atrophy) and QOL, suggesting the potential utility of patientreported QOL as a clinical outcome in trials [15] [16] [17] . The objective of this study was to determine the relative impact of cervical cord atrophy as compared to cord and brain lesions and whole brain atrophy on quality-of-life in MS. 
Methods:

Subjects
MRI Acquisition
All subjects underwent brain and cervical spine MRI at 3T using the same scanner and 20-channel craniospinal coil (3T Skyra, Siemens Medical Solutions, Erlangen, Germany). MRI acquisition protocols were identical among subjects. Head scans covered the whole brain and included 3D high-resolution T1-weighted sagittal magnetization-prepared rapid gradient-echo 
both the whole head and extended to the C5 vertebral level to cover the upper cervical spinal cord. Brain and spinal cord images were repeated five minutes after IV administration of 0.1 mmole/kg of gadolinium.
MRI Analysis
Upper cervical cord area (UCCA) measurement: Sample images and contouring are illustrated in Figure 1 . Original DICOM images were converted to NIfTI format using Jim 7.0 (Xinapse Systems Ltd., West Bergholt, UK; http://www.xinapse.com). UCCA measurements were obtained at C1-C3 vertebral levels from the MPRAGE images, using a semi-automated active surface contouring pipeline [19] . To calculate cord area, 1-mm-thick reconstructed axial slices perpendicular to the cord axis from C1-C3 were sampled every 5 mm using the semiautomated Jim software "cord finder toolbox" with fixed settings (nominal cord diameter = 8 mm, number of shape coefficients = 24, order of longitudinal variation = 12).
Toolkit markers were placed at the center of images and spinal cord contour was determined using a reproducible active surface tool. Sagittal native images were cross-referenced to identify vertebral levels precisely ( Figure 1 Brain and cervical cord lesion measurement: Sample images and contouring are illustrated in Figure 2 . Whole-brain T2 hyperintense lesion volume (T2LV) was calculated using a semi-automated edge-finding tool in Jim 7.0 software on the axial brain T2 FLAIR sequence.
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Statistical Analysis
Statistical correlations between MRI metrics, clinical variables, and QOL domains were assessed by Spearman correlation coefficients. Partial Spearman correlation coefficients were calculated adjusting for age, disease duration, and BPF to assess the independent association between MRI variables and QOL domains. Partial Spearman correlation coefficients were calculated using the ppcor library in R (www.r-package.org). A p <0.05 was considered statistically significant.
Results
Upper Cervical Cord Area: Clinical Outcomes & QOL
UCCA showed inverse correlations with age (r= -0.330, p=0.009) and disease duration 
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Differential Impact of Cervical Atrophy vs. Lesions
Cervical T2LV showed no significant relationship to age or disease duration and correlated poorly with NeuroQOL (Table 2) . Only a weakly significant relationship to increased Stigma (r=0.258, p=0.045) was observed. The correlation was similar after adjustment for age, disease duration, and whole brain atrophy, though statistical significance was decreased (Supplementary Table 1 ). The significant inverse relationship between UCCA and Upper Extremity Function QOL was not seen between cervical T2LV and Upper Extremity Function QOL ( Table 2) . A mean 3.5 ±2.6 (0-11) cervical lesions were identified in this cohort, though cervical lesion number was not related to any QOL domain (data not shown). The relative impact of UCCA versus cervical T2LV on QOL was not different after removing CIS subjects (n=2) or African American subjects (n=3) (data not shown).
Brain T2 Lesions and Atrophy: Clinical Outcomes & QOL
Brain T2LV strongly inversely correlated with cognitive function as assessed by SDMT (r= -0.576, p<0.001) but had no relationship to other disability outcomes or demographic characteristics (Table 3) . Stigma (r=-0.271 p=0.033) was the only NeuroQOL domain to show a significant pathological relationship with Brain T2LV; a borderline significant association with Cognition domain impairment was also noted (Table 3) . A statistical correlation with Emotional and Behavioral Dyscontrol QOL was noted though the directionality was not consistent with a pathological correlation ( Table 3) . None of these correlations persisted in adjusted analyses accounting for whole brain atrophy (Supplementary Table 1 ). BPF showed an inverse correlation with age (r= -0.268, p=0.037) and disease duration (r= -0.302, p=0.018), as well as traditional measures of MS-related disability [EDSS (r= -0.449, p=<0.001), T25FW (r= -0.240, p=0.063),
9HPT (r= -0.315, p=0.014), SDMT Sum Score (r=0.488, p=<0.001)], however there was only a weak borderline significant association with Emotional Dyscontrol QOL (r=0.238, p=0.065) and no significant relationship with other QOL domains (Table 3) .
Other MRI results Table 4 shows the relationship among MRI variables investigated in this study. UCCA
showed no relationship to cervical T2LV or cervical lesion number, though cervical T2LV and cervical lesion number showed strong positive correlations with each other (r=0.849, p=<0.001) ( Table 4) . UCCA also showed a stronger association with brain atrophy (r=0.451, p<0.001) than with brain T2LV (r=-0.271, p=0.033) ( Table 4) . Weaker associations, but with similar magnitude, were noted between brain T2LV, cervical lesion number, T2LV and UCCA (Table   4) . No subjects had gadolinium contrast-enhancing lesions in the brain or spinal cord.
Discussion:
The purpose of this study was to investigate relative impact of cervical cord atrophy as compared to lesions in the spinal cord and both brain lesion and atrophy on QOL in MS. Our results showed that cervical spinal cord atrophy had a significant independent association with NeuroQOL impairment related to upper extremity mobility and borderline significant relationship to lower extremity mobility and satisfaction with social roles. Cervical T2 lesion burden, by comparison, correlated poorly with extremity QOL, and showed only modest relationship to stigma. Brain T2LV was related to impaired cognition and increased stigma, .020) but not between brain or cervical T2LV and EDSS score [26] . In our study, UCCA, but not cervical T2LV, showed correlation with many standard clinical variables (EDSS, ambulation time, 9HPT) ( Table 2 ) supporting findings form prior work implicating higher clinical relevance of cervical atrophy as compared to cervical T2 lesions to physical disability [26] . Lastly, prior work also showed a poor relationship between spinal cord and brain MRI involvement in MS, with respect to both lesions and atrophy [26] , suggesting that these topographic specific aspects of the disease progress somewhat independently. These findings are consistent with our data. [15] . Lastly, we did find an association between brain T2LV and increased Stigma ("Perceptions of self and publicly enacted negativity, prejudice and discrimination as a result of disease-related manifestations") and worse SDMT score as well as a weak association between brain atrophy and Emotional Dyscontrol, and these outcomes overlap with QOL assessed by FAMS Emotional
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Wellbeing and Thinking/Fatigue subscales.
Our study has several limitations that warrant discussion. First, the generalizability of our results is limited by cohort clinical/demographic characteristics. Patients in this study were
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A N U S C R I P T 13 generally mildly disabled, predominantly of RRMS subtype, and had a low mean cervical lesion number and volume, which may have limited the power to detect correlations with QOL. Our study was not powered to evaluate group differences between RRMS and SP/PPMS subgroups, and prior work has demonstrated that cervical atrophy may have less clinical impact in RRMS [27] ; thus, larger studies are needed to interpret how the MRI-QOL correlations observed in our cohort apply to specific disease stages. Secondly, the stability of MRI-QOL associations we identified and their relationship to disease progression is unclear as longitudinal change was not analyzed. Recent work indicates that decline in UCCA is related to impending disease progression and disability [8, [12] [13] [14] , though the impact on health-related QOL has not been investigated. We are currently in the process of collecting longitudinal clinical and QOL data at our center. In future studies, we plan to evaluate serial relationships between MRI and QOL to assess how early spinal cord involvement may predict QOL impairment and progression.
Thirdly, there are limitations in the use of NeuroQOL for the evaluation of health related QOL.
In this work we used a computer-adapted version of NeuroQOL that differs slightly from the short form version that was formally validated in MS. Self-report/recall of QOL can be limited in patients with MS as a result of cognitive impairment. Furthermore, QOL "appraisal"-the way individuals think about their QOL-impacts measurement, and for example, may lead to underestimation of QOL burden related to long-standing deficits [28] . This may help account for shown association between thoracic atrophy and MS disability [29] , and the relationship to QOL is not known. Further studies are needed to investigate how other MRI measurements linked to disease progression (e.g. deep grey matter [30] , brainstem [31] , and cortical [32] involvement) correlate with patient QOL. We did not explore the effect of treatment on MRI-QOL relationships as this study was not powered to assess this, though treatment effects (presumably leading to milder MRI and improved QOL) should be investigated in larger cohorts.
Nonetheless, this study adds to the growing understanding that spinal cord involvement can often help to bridge the gap between brain involvement and disability (clinical-MRI dissociation) in MS [33] .
Conclusions:
Cervical spinal cord atrophy is independently related to impairment in upper extremity mobility QOL, whereas cervical lesions correlate poorly with NeuroQOL. Cervical cord atrophy better correlates with traditional markers of clinical disability as compared to total cervical or brain lesion load, which has a distinct effect on stigma QOL and cognition. These findings highlight the complimentary information provided by brain and spinal cord lesion volume and atrophy in the assessment of MS severity.
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